美國新特藥在取得食品藥物管理局（FDA）核准上市並公布定價後，經常面臨所謂的「編碼落差」（coding gap）問題，導致藥品償付（reimbursement，即醫療保險支付藥品費用）延遲。這種延遲不僅影響了藥品的實際可及性，也對醫療體系帶來挑戰。
Outlook Therapeutics, Inc.: prezzi di Borsa, grafici, quotazioni, consigli di Borsa, dati finanziari, analisi e notizie in ...
Outlook Therapeutics, Inc.: Cours de bourse, graphiques, cotations, conseils boursiers, données financières, analyses et actualités en temps réel Action Outlook Therapeutics, Inc. | OTLK | US69012T305 ...
HCPCS code E0150 — defined as “Combination wheeled walker with seat and transport chair, folding, adjustable or fixed height” ...
CMS finalizes mandatory GLOBE Model implementing Most Favored Nation drug pricing in Medicare Part B
On September 30, 2026, the Centers for Medicare & Medicaid Services (CMS) finalized a rule to implement a mandatory Most ...
Home medical equipment (HME) stakeholders had several high-level meetings scheduled the week of Sept. 28, including with the Office of Management and Budget (OMB), to discuss the expected negative imp ...
ISELIN - Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA (bevacizumab-vikg, bevacizumab gamma) for the treatment of ...
Outlook Therapeutics, Inc. hat bekannt gegeben, bei den Centers for Medicare & Medicaid Services einen Antrag auf Erteilung eines dauerhaften, produktspezifischen J-Codes der Stufe II des Healthcare..
Outlook Therapeutics, Inc. announced that it has submitted an application to the Centers for Medicare & Medicaid Services (CMS) requesting a permanent, product-specific Healthcare Common Procedure ...
Application represents an important step in supporting reimbursement Company remains on track for U.S. commercial launch of LYTENAVA before year-end 2026 ISELIN, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) ...
Application represents an important step in supporting reimbursement Company remains on track for U.S. commercial launch of LYTENAVA before year-end 2026 ISELIN, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) - ...
Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results